In conclusion, these findings suggest that the anti-tumor mechanism of BRU and PD combined therapy inhibits Nrf2/HO-1 and NQO1 signaling pathways while increasing ROS levels, which has a toxic effect on BC cells and inhibits cell proliferation. This evidence concerns the gene NFE2L2 and breast cancer.